02 August 2018
Visiongain’ has launched a new pharma report Global Anaesthesia Drugs Market 2018-2028: Local Anaesthesia, General Anaesthesia, Inhalation Anaesthesia, Intravenous Anaesthesia, Topical Anaesthesia
This anaesthesia drugs market can be broadly segmented into type and routes of administration. The market is segregated further by type as local anaesthesia and general anaesthesia. Inhalation intravenous and topical are the main forms of routes of administration. The market has also been geographically segmented into North America (US, Canada), Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Asia-Pacific (India, China, Japan, Rest of Asia-Pacific), Rest of World (Brazil, Mexico, Russia, South Africa).
The lead analyst of the report commented “The global anaesthesia drugs market is projected to grow at lucrative rate during the forecast period owing to a rising number of surgical procedures globally, developing healthcare infrastructure in emerging economies, and growing number of geriatric population. The escalating prevalence of cancer, stroke, arthritis, and neurological diseases leads to a rising number of surgical procedures. In addition, rising number of road accidents and trauma cases will further drive the growth of the market.”
Leading companies featured in the report include Baxter International, Inc., AbbVie, PAION AG, Pfizer, Hameln Pharmaceuticals, AstraZeneca, Fresenius Kabi, Maruishi Pharmaceuticals, Pacira Pharmaceuticals, Inc
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.
15 August 2019
The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.
06 August 2019
The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.
02 August 2019
It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.